Introducing new vaccines in developing countries

Expert Review of Vaccines

Volumn 12, Issue 12, 2013, Pages 1465-1478

  Kochhar, Sonali ^a   Rath, Barbara ^b   Seeber, Lea D ^b   Rundblad, Gabriella ^c   Khamesipour, Ali ^d   Ali, Mohammad ^e  

^a PATH   (India)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e International Vaccine Institute   (South Korea)

Author keywords

AEFI; developing countries; immunization; vaccine introduction; vaccine safety; vaccines

Indexed keywords

NEW DRUG; SMALLPOX VACCINE; VACCINE;

COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DEVELOPING COUNTRY; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG RESEARCH; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EDUCATION PROGRAM; EVIDENCE BASED MEDICINE; HEALTH CARE PERSONNEL; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH EDUCATION; HEALTH PROGRAM; HEALTH PROMOTION; HUMAN; IMMUNIZATION; INFECTION; INJECTION; KNOWLEDGE; NEEDLESTICK INJURY; PRIORITY JOURNAL; REVIEW; SMALLPOX; STAFF TRAINING; VACCINATION; WORLD HEALTH ORGANIZATION;

COMMUNICABLE DISEASES; DEVELOPING COUNTRIES; HUMANS; VACCINATION; VACCINES;

EID: 84887679718     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2013.855612     Document Type: Review

References (79)

1. Vandersmissen W. WHO expectation and industry goals. Vaccine 19 (13-14), 1611-1615 (2001).
2. UN. World Economic Situation and Prospects. United Nations, NY, USA, 143-152 (2013).
3. Plotkin SA, Orenstein WA, Offit PA. Vaccines. Saunders Elsevier, Philadelphia, PA, USA (2008).
4. Nabel GJ. Designing tomorrow's vaccines. N. Engl. J. Med. 368(6), 551-560 (2013).
5. Muehlhans S, Richard G, Ali M et al. Safety reporting in developing country vaccine clinical trials-a systematic review. Vaccine 30(22), 3255-3265 (2012).
6. CDC. Progress toward introduction of Haemophilus influenzae type b vaccine in low-income countries-worldwide, 2004-2007. MMWR Morb. Mortal. Wkly Rep 57(6), 148-151 (2008).
7. Merten S, Schaetti C, Manianga C et al. Local perceptions of cholera and anticipated vaccine acceptance in Katanga province, Democratic Republic of Congo. BMC Public Health 13, 60 (2013).
8. Mueller JE. Conjugate vaccine introduction in the African meningitis belt: meeting surveillance objectives. Trop. Med. Int. Health 18(1), 58-64 (2013).
9. Soeung SC, Grundy J, Maynard J et al. Financial sustainability planning for immunization services in Cambodia. Health Policy Plann. 21(4), 302-309 (2006).
10. Mahoney RT, Maynard JE. The introduction of new vaccines into developing countries. Vaccine 17(7-8), 646-652 (1999).
11. Sahay S, Mehendale SM. Engaging community to support HIV prevention research. East. J. Med. 16, 168-177 (2011).
12. Steele AD, Patel M, Parashar UD, Victor JC, Aguado T, Neuzil KM. Rotavirus vaccines for infants in developing countries in Africa and Asia: considerations from a world health organization-sponsored consultation. J. Infect. Dis. 200(Suppl. 1), S63-S69 (2009).
13. Letourneau M, Wells G, Walop W, Duclos P. Improving global monitoring of vaccine safety: a survey of national centres participating in the WHO programme for international drug monitoring. Drug Saf. 31(5), 389-398 (2008).
14. Graham JE, Borda-Rodriguez A, Huzair F, Zinck E. Capacity for a global vaccine safety system: the perspective of national regulatory authorities. Vaccine 30(33), 4953-4959 (2012).
15. Dodoo A, Hugman B. Risk perception and communication in sub-Saharan Africa. Drug Saf. 35(11), 1041-1052 (2012).
16. Zaman K, Yunus M, El Arifeen S et al. Methodology and lessons-learned from the efficacy clinical trial of the pentavalent rotavirus vaccine in Bangladesh. Vaccine 30 (Suppl. 1), A94-A100 (2012).
17. Fields R, Dabbagh A, Jain M, Sagar KS. Moving forward with strengthening routine immunization delivery as part of measles and rubella elimination activities. Vaccine 31 (Suppl. 2), B115-B121 (2013).
18. Griffiths UK, Santos AC, Nundy N, Jacoby E, Matthias D. Incremental costs of introducing jet injection technology for delivery of routine childhood vaccinations: comparative analysis from Brazil, India, and South Africa. Vaccine 29(5), 969-975 (2011).
19. Fleming JA, Hoekstra EJ, Moniaga V et al. Reuse prevention syringes for reconstitution of lyophilized vaccines: Operational study and UNICEF plans for expanding introduction. Int. J. Occup. Environ. Health 15(1), 9-13 (2009).
20. Burnett RJ, Larson HJ, Moloi MH et al. Addressing public questioning and concerns about vaccination in South Africa: a guide for health care workers. Vaccine 30(Suppl. 3), C72-C78 (2012).
21. Ismail NA, Aboul Ftouh AM, El-Shoubary WH, Mahaba H. Safe injection practice among health-care workers in Gharbiya Governorate, Egypt. East. Mediterr. Health J. 13(4), 893-906 (2007).
22. Gyawali S, Rathore DS, Kc B, Shankar PR. Study of status of safe injection practice and knowledge regarding injection safety among primary health care workers in Baglung district, western Nepal. BMC Int. Health Human Rights 13, 3 (2013).
23. Vorsters A, Tack S, Hendrickx G et al. A summer school on vaccinology: responding to identified gaps in pre-service immunisation training of future health care workers. Vaccine 28(9), 2053-2059 (2010).
24. Mutabaruka E, Dochez C, Nshimirimana D, Meheus A. Evaluation of mid-level management training in immunisation in the African region. East Afr. J. Publ. Health 7(1), 37-43 (2010).
25. Attaullah S, Khan S, Naseemullah et al. Prevalence of HBV and HBV vaccination coverage in health care workers of tertiary hospitals of Peshawar, Pakistan. Virol. J. 8, 275 (2011).
26. Oria PA, Matini W, Nelligan I et al. Are Kenyan health care workers willing to receive the pandemic influenza vaccine? Results from a cross-sectional survey of health care workers in Kenya about knowledge, attitudes and practices concerning infection with and vaccination against 2009 pandemic influenza A (H1N1), 2010. Vaccine 29(19), 3617-3622 (2011).
27. Katahoire RA, Jitta J, Kivumbi G et al. An assessment of the readiness for introduction of the HPV vaccine in Uganda. Afr. J. Reprod. Health 12(3), 159-172 (2008).
28. Bingham A, Drake JK, LaMontagne DS. Sociocultural issues in the introduction of human papillomavirus vaccine in low-resource settings. Arch. Pediatr. Adolesc. Med. 163(5), 455-461 (2009).
29. Braka F, Asiimwe D, Soud F, Lewis RF, Makumbi I, Gust D. A qualitative analysis of vaccine safety perceptions and concerns among caretakers in Uganda. Matern. Child Health J. 16(5), 1045-1052 (2012).
30. Suresh PS, Thejaswini V, Rajan T. Factors associated with 2009 pandemic influenza A (H1N1) vaccination acceptance among university students from India during the post-pandemic phase. BMC Infect. Dis. 11, 205 (2011).
31. Chaibou MS, Bako H, Salisou L et al. Monitoring adverse events following immunization with a new conjugate vaccine against group A meningococcus in Niger, September 2010. Vaccine 30(35), 5229-5234 (2012).
32. Iacobucci G. Wales sets up drop-in vaccination clinics to tackle measles outbreak. BMJ (Clin. Res. Ed.) 346, f2452 (2013).
33. Wise J. Largest group of children affected by measles outbreak in Wales is 10-18 year olds. BMJ (Clin. Res. Ed.) 346, f2545 (2013).
34. MSF. Weekly Update: Oral Cholera Vaccination campaign (OCV)-15 January 2012. In: Weekly Update: Oral Cholera Vaccination campaign (OCV). Medecins Sans Frontieres (MSF), Geneva, Switzerland (2012)
35. Ali M, Emch M, von Seidlein L et al. Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. Lancet 366(9479), 44-49 (2005).
36. Khatib AM, Ali M, von Seidlein L et al. Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study. Lancet Infect. Dis. 12(11), 837-844 (2012).
37. Ali M, Emch M, Yunus M et al. Vaccine Protection of Bangladeshi infants and young children against cholera: implications for vaccine deployment and person-to-person transmission. Pediatr. Infect. Dis. J. 27(1), 33-37 (2008).
38. Liheluka EA, Lusingu JP, Manongi RN. Community perceptions on the secondary health benefits established by malaria vaccine trials (RTS,S Phase II and Phase III) at the Korogwe site in North Eastern Tanzania. Malar. J. 12, 157 (2013).
39. Letourneau M, Wells G, Walop W, Duclos P. Improving global monitoring of vaccine safety: A quantitative analysis of adverse event reports in the WHO adverse reactions database. Vaccine 26(9), 1185-1194 (2008).
40. Lawrence G, Menzies R, Burgess M et al. Surveillance of adverse events following immunisation: Australia, 2000-2002. Commun. Dis. Intell. 27(3), 307-323 (2003).
41. Chen RT, Rastogi SC, Mullen JR et al. The vaccine adverse event reporting system (VAERS). Vaccine 12(6), 542-550 (1994).
42. Zhou W, Pool V, Iskander JK et al. Surveillance for safety after immunization: vaccine adverse event reporting system (VAERS)-United States, 1991-2001. MMWR Surveill. Summ 52(1), 1-24 (2003).
43. Martin D, Menschik D, Bryant-Genevier M , Ball R. Data mining for prospective early detection of safety signals in the Vaccine Adverse Event Reporting System (VAERS): A case study of febrile seizures after a 2010-2011 seasonal influenza virus vaccine. Drug Saf. 36(7), 547-556 (2013).
44. Haber P, Patel M, Pan Y et al. Intussusception After Rotavirus Vaccines Reported to US VAERS, 2006-2012. Pediatrics (2013).
45. Lawrence GL, Burgess MA, Kass RB. Age-related risk of adverse events following yellow fever vaccination in Australia. Commun. Dis. Intell. 28(2), 244-248 (2004).
46. Menzies R, Mahajan D, Gold MS, Roomiani I, McIntyre P, Lawrence G. Annual report: surveillance of adverse events following immunisation in Australia, 2008. Commun. Dis. Intell. 33(4), 365-381 (2009).
47. Lee H, Kim HW, Cho HK, Park EA, Choi KM, Kim KH. Reappraisal of MMR vaccines currently used in Korea. Pediatr. Int. 53(3), 374-380 (2011).
48. Huang WT, Chen WC, Teng HJ et al. Adverse events following pandemic A (H1N1) 2009 monovalent vaccines in pregnant women-Taiwan, November 2009-August 2010. PLoS ONE 6(8), e23049 (2011).
49. Kim JH, Cho HY, Hennessey KA, Lee HJ, Bae GR, Kim HC. Adverse events following immunization (AEFI) with the novel influenza a (H1N1) 2009 vaccine: findings from the national registry of all vaccine recipients and AEFI and the passive surveillance system in South Korea. Jpn J. Infect. Dis. 65(2), 99-104 (2012).
50. Pless RP, Bentsi-Enchill AD, Duclos P. Monitoring vaccine safety during measles mass immunization campaigns: clinical and programmatic issues. J. Infect. Dis. 187 (Suppl. 1), S291-S298 (2003).
51. Olsson S. The role of the WHO programme on International Drug Monitoring in coordinating worldwide drug safety efforts. Drug Saf. 19(1), 1-10 (1998).
52. Dasgupta S, Bagchi SN, Ghosh P, Sardar JC, Roy AS, Sau M. Monitoring of mass measles campaign in AILA-affected areas of West Bengal. Indian J. Publ. Health 54(4), 224-227 (2010).
53. Latipov R, Khudoyorov R, Flem E. Childhood intussusception in Uzbekistan: analysis of retrospective surveillance data. BMC Pediatr. 11, 22 (2011).
54. Clemens J, Jodar L. Introducing new vaccines into developing countries: obstacles, opportunities and complexities. Nat. Med. 11(Suppl. 4), S12-S15 (2005).
55. Lankinen KS, Pastila S, Kilpi T, Nohynek H, Makela PH, Olin P. Vaccinovigilance in Europe-need for timeliness, standardization and resources. Bull. World Health Organ. 82(11), 828-835 (2004).
56. Kirigia JM, Gbary AR, Muthuri LH, Nyoni J, Seddoh AT. The cost of health professionals brain drain in Kenya. BMC Health Serv. Res. 6(1), 89 (2006).
57. Hagopian A, Ofosu A, Fatusi A et al. The flight of physicians from West Africa: views of African physicians and implications for policy. Soc. Sci. Med. 61(8), 1750-1760 (2005).
58. Tugumisirize F, Tumwine JK, Mworozi EA. Missed opportunities and caretaker constraints to childhood vaccination in a rural area in Uganda. East Afr. Med. J. 79(7), 347-354 (2002).
59. Miller E, Batten B, Hampton L, Campbell SR, Gao J, Iskander J. Tracking vaccine-safety inquiries to detect signals and monitor public concerns. Pediatrics 127 (Suppl. 1), S87-S91 (2011).
60. Huang WT, Chuang JH, Kuo SH. Monitoring the safety of pandemic H1N1 vaccine. Lancet 375(9721), 1164 (2010).
61. Larson HJ, Smith DM, Paterson P et al. Measuring vaccine confidence: analysis of data obtained by a media surveillance system used to analyse public concerns about vaccines. Lancet Infect. Dis. 13(7), 606-613 (2013).
62. Wallerstein N, Duran B. Community-based participatory research contributions to intervention research: the intersection of science and practice to improve health equity. Am. J. Publ. Health 100(Suppl. 1), S40-S46 (2010).
63. Brownson RC, Fielding JE, Maylahn CM. Evidence-based public health: a fundamental concept for public health practice. Annu. Rev. Publ. Health 30, 175-201 (2009).
64. Sahay TB, Rempel B, Lodge J. Equipping public health professionals for youth engagement: lessons learned from a 2-year pilot study. Health Promot. Pract. (2012) (Epub ahead of print).
65. Sahay S, Reddy KS, Dhayarkar S. Optimizing adherence to antiretroviral therapy. Indian J. Med. Res. 134(6), 835-849 (2011).
66. Tartof S, Cohn A, Tarbangdo F et al. Identifying Optimal Vaccination Strategies for Serogroup A Neisseria meningitidis Conjugate Vaccine in the African Meningitis Belt. PLoS ONE 8(5), e63605 (2013).
67. Patel MM, Parashar UD. Assessing the effectiveness and public health impact of rotavirus vaccines after introduction in immunization programs. J. Infect. Dis. 200 (Suppl. 1), S291-S299 (2009).
68. Lopman BA, Payne DC, Tate JE, Patel MM, Cortese MM, Parashar UD. Post-licensure experience with rotavirus vaccination in high and middle income countries; 2006-2011. Curr. Opin. Virol. 2(4), 434-442 (2012).
69. Live Dengue Vaccines Technical Consultation Reporting Group; Bentsi-Enchill AD, Schmitz J et al. Long-term safety assessment of live attenuated tetravalent dengue vaccines: deliberations from a WHO technical consultation. Vaccine 31(23), 2603-2609 (2013).
70. Douglas DL, DeRoeck DA, Mahoney RT, Wichmann O. Will dengue vaccines be used in the public sector and if so, how? Findings from an 8-country survey of policymakers and opinion leaders. PLoS Neglected Trop. Dis. 7(3), e2127 (2013).
71. Vashishtha VM, Kumar P. 50 years of immunization in India: progress and future. Indian Pediatr. 50(1), 111-118 (2013).
72. Chokshi DA, Kesselheim AS. Rethinking global access to vaccines. BMJ (Clin. Res. Ed.), 336(7647), 750-753 (2008).
73. Rath B, Ali M, Elemuwa C et al. Prioritizing polio. Expert Rev.Vacc. 11(12), 1389-1392 (2012).
74. Simons E, Ferrari M, Fricks J et al. Assessment of the 2010 global measles mortality reduction goal: results from a model of surveillance data. Lancet 379(9832), 2173-2178 (2012).
75. Kamara L, Lydon P, Bilous J et al. Global Immunization Vision and Strategy (GIVS): a mid-term analysis of progress in 50 countries. Health Pol. Plann. 28(1), 11-19 (2013).
76. Bilous J, Eggers R, Gasse F et al. A new global immunisation vision and strategy. Lancet 367(9521), 1464-1466 (2006).
77. Muraskin W. The Global Alliance for Vaccines and Immunization: is it a new model for effective public-private cooperation in international public health? Am. J. Publ. Health 94(11), 1922-1925 (2004).
78. Wonodi CB, Privor-Dumm L, Aina M et al. Using social network analysis to examine the decision-making process on new vaccine introduction in Nigeria. Health Policy Plann. 27(Suppl. 2), ii27-ii38 (2012).
79. Clemens J, Shin S, Ali M. New approaches to the assessment of vaccine herd protection in clinical trials. Lancet Infect. Dis. 11(6), 482-487 (2011).